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Abstract
Hepatocellular carcinoma (HCC) represents an increasing fraction of liver transplant indications;
the role of living donor liver transplant (LDLT) remains unclear. Recurrence and post-transplant
mortality rates were compared in LDLT and deceased donor liver transplant (DDLT) patients with
at least one potential living donor evaluated. HCC recurrence and post-transplant mortality were
evaluated among 100 LDLT and 97 DDLT recipients in the Adult-to-Adult Living Donor Liver
Transplantation Cohort Study. Mortality from date of evaluation of each recipient’s first potential
living donor was analyzed. LDLT recipients had shorter time to transplant, were more likely to
have tumors exceeding Milan criteria, higher alpha-fetoprotein levels, and less likely to have
received pre-operative loco-regional therapy than DDLT recipients. Unadjusted 5-year HCC
recurrence was significantly higher after LDLT (38%) than DDLT (11%), (p=0.0004). After
adjustment for tumor characteristics, HCC recurrence remained significantly different between
LDLT and DDLT recipients (hazard ratio (HR) = 2.35; p=0.04) for the overall cohort but not for
recipients transplanted following the introduction of MELD prioritization. Five-year post-
transplant survival was similar in LDLT and DDLT recipients from time of transplant (HR=1.32;
p=0.27) and from date of LDLT evaluation (HR=0.73; p=0.36). We conclude that the higher
recurrence observed after LDLT is likely due to differences in tumor characteristics, pre-transplant
HCC management, and waiting time.
Keywords
Recurrence; MELD score; Milan criteria; loco-regional therapy; survival
Introduction
Liver transplantation (LT) is a well established therapeutic option in patients with
unresectable hepatocellular carcinoma (HCC). The rate of recurrent HCC had been reported
to be significantly higher following living donor liver transplant (LDLT) compared to
deceased donor liver transplant (DDLT), even after adjustment for tumor stage (1–3). The
reasons for this observation remain speculative. In the United States, enhanced prioritization
for DDLT for candidates with HCC is limited to those fulfilling the Milan criteria, leaving
LDLT as the only timely route to transplantation without the delay and uncertainty of
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downstaging for those with more advanced lesions. Anticipated prolonged waiting times for
DDLT, with the risk of drop out due to tumor progression, may also provide motivation to
pursue LDLT. Differences in expected waiting times in DDLT and LDLT can influence pre-
transplant management, specifically resulting in less application of loco-regional therapies
(LRT) prior to LDLT due to shorter waiting times.
The Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) consortium
previously reported a 3-year HCC recurrence probability of 29% following LDLT vs. 0%
following DDLT in a cohort of 92 recipients (p = 0.002) (1). The majority of these patients
(57%) were transplanted prior to the introduction of Model for End-Stage Liver Disease
(MELD). Since the publication of our original report, the number of HCC patients who have
undergone transplantation in the A2ALL study has more than doubled, and the median
duration of follow-up following transplant has increased from 3.7 to 4.9 years. Moreover,
the results reported in the earlier study were derived largely from a retrospective cohort. The
main aims of this study were to compare recurrence and mortality following LDLT or
DDLT. We also analyzed survival from the time of the donor’s evaluation in an intention-to-
treat analysis among those who had at least one potential living donor evaluated; we
compared those who underwent LDLT versus those who did not receive an LDLT (LDLT
candidates who received a DDLT plus those who had a potential living donor evaluated but
were not transplanted at all).
Methods
The A2ALL Study Consortium consists of 9 clinical centers and a data coordinating center.
The overall design of the A2ALL Study had been described previously (4). Entry into the
study was defined as the date of evaluation (history and physical examination) of the first
potential live donor for a given transplant candidate. Subsequently, some patients underwent
a LDLT and the remainder continued to wait for a DDLT. Data were obtained from
retrospective chart review from January 1, 1998 to February 28, 2003, and using a
combination of retrospective and prospective collection from February, 28, 2003 through
August 31, 2010. The study was approved by the Institutional Review Board and Privacy
Boards of the Data Coordinating Center at the University of Michigan and the 9
participating centers. All patients in the prospective study provided written informed consent
for participation.
Among a total of 1528 patients with a potential live donor evaluated between 01/01/98 and
08/31/09, 229 patients had known HCC prior to transplant, representing the cohort for this
study. Since candidates with HCC within Milan criteria were given higher priority for
DDLT in the MELD era beginning in February 2002, we also analyzed the results of
subjects whose first potential donor underwent evaluation after the implementation of the
MELD-based system.
Laboratory MELD score, alphafetoprotein (AFP) level, tumor characteristics, and receipt of
LRT were recorded at donor evaluation and at LT. The type of LRT and the number of
treatments prior to LT were not standardized across centers. Computed tomography or MRI
was performed every 3–6 months until LT. Tumor staging pre-LT according to the modified
Tumor Node Metastasis (TNM) staging system, Milan criteria, and University of California
San Francisco (UCSF) criteria were based on local interpretation of radiologic imaging (5–
7). Explant pathology was reviewed locally; the number, location, and size of viable tumor
nodules, presence of macroscopic/microscopic vascular invasion, and Edmonson tumor
grade were recorded. Patients were followed until the data censoring date – August 31, 2010
or death. Imaging and AFP levels were obtained post-transplant every 6 months for the first
2 years, and thereafter according to a schedule determined by the individual centers.
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Descriptive statistics are presented as mean and standard deviation (SD) or percentage, and
patient characteristics were compared by transplant type (LDLT or DDLT) using two-
sample t-tests and chi-square tests. Kaplan-Meier estimates were computed for the three
study outcomes, all computed as time from transplant: time to HCC recurrence, overall
survival, and recurrence-free survival. The outcomes for LDLT and DDLT patients were
compared by log-rank test. The probabilities of each of the competing risks of receiving
LDLT or DDLT, dying on the waitlist, and remaining alive without a transplant were
estimated using the cumulative incidence function, computed by the SAS macro ‘comprisk’
developed at Mayo clinic (8). This function is displayed for both the pre-MELD and MELD
eras.
Multivariable Cox models were used to assess predictors of HCC recurrence, overall
survival, and recurrence-free survival from time of transplant. Potential predictors included
type of transplant, recipient age, recipient race, AFP at transplant, lab MELD at transplant,
number of LRT prior to transplant, evaluation period (pre/post MELD), waiting time from
donor evaluation to transplant, etiology of cirrhosis, and the following explant
characteristics: number of tumor nodules, size of largest nodule, tumor grade (G1-G3), and
vascular invasion. Model selection was performed using the best subsets selection method
(9). Hazard ratios (HR) and corresponding 95% confidence intervals (CI) were reported for
each prognostic factor in the final models. Sub-analyses were also performed for patients
evaluated in the MELD era (after February 28, 2002). Centers were considered to be
experienced in LDLT after 20 patients received LDLT.
Patient survival from the time of donor evaluation was analyzed to evaluate the benefit of
LDLT compared to waiting for, and possibly receiving, a DDLT. This analysis used the
sequential stratification modification of Cox regression, adjusted for baseline covariates of
recipient age, recipient race, AFP, laboratory MELD, number of LRT, and tumor stage, each
assessed at the time of the subject’s first donor evaluation (6).
The practice patterns of individual transplant centers, including criteria for transplantation
(radiographic tumor staging and AFP levels at transplant) and the utilization of LRT prior to
transplantation, as well as waiting time to transplant, differed among the centers. Statistical
tests of center associations with post-transplant outcomes were limited by the small number
of cases at individual transplant centers.
Data were analyzed by the Data Coordinating Center at the University of Michigan using
SAS 9.2 software (SAS Institute Inc., Cary, NC).
Results
Patient Characteristics at Donor Evaluation and at Transplant
Characteristics of the entire cohort at donor evaluation and at transplant are shown in Tables
1 and 2. There were no significant differences between LDLT and DDLT recipients in terms
of demographic variables or calculated MELD score. At evaluation, the LDLT recipients
had evidence of more advanced HCC with significantly higher AFP levels and a larger
tumor burden (both a greater size of largest nodule and higher percentage exceeding Milan
and UCSF criteria). LDLT recipients were significantly less likely to have received any
form of ablative therapy (radiofrequency ablation, transarterial chemoembolization,
radioembolization) and among those who received ablative therapy, LDLT recipients had
less ablation sessions than DDLT recipients (1.2 vs. 1.8; p = 0.01). At transplant, differences
in tumor staging based on radiologic imaging and LRT received persisted. However, the
differences were attenuated when comparisons were based on transplant pathology (Table
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2). LDLT patients had significantly shorter mean waiting times between donor evaluation
and transplant compared to DDLT recipients, (77.7 vs. 180.5 days, p = 0.0004). Donor age
was significantly younger and cold ischemia time significantly shorter among LDLT
recipients. Similar differences were noted for patients in the MELD era (N = 126)
(Supplementary Tables 1 and 2).
Transplant Timing and Donor Type
Of the 229 HCC patients, 100 received a LDLT, 97 a DDLT and 32 had not undergone
transplantation at the time of data analysis. Among the 32 patients who did not receive a
transplant, 27 died awaiting transplantation (median time from donor evaluation to death
11.9 months, range 0.3 – 79 months) and 5 withdrew consent from the A2ALL (median time
from donor evaluation to last follow up 8.6 months, range 0.2 – 50 months). Of the 146
patients enrolled in the MELD era, 50 received a LDLT, 76 a DDLT, and 20 had not
undergone transplantation. The principal difference in the experience of transplant
candidates between the two eras was a shift to DDLT in the MELD era (Figure 1). In the
pre-MELD era, 60% of candidates received LDLT and 24% received DDLT, whereas in the
MELD era, 35% received LDLT and 54% received DDLT. The proportion who died without
LT was 10% in both eras.
Explant Pathology
LDLT recipients compared with DDLT recipients were more likely to have tumors
exceeding the Milan (56% vs. 44%, p = 0.10) and UCSF criteria (48% vs. 34%, p = 0.06), to
have significantly larger tumors (p = 0.01) and were more likely to have vascular invasion (p
= 0.07) (Table 2). LDLT recipients in the MELD era also had significantly larger tumors (p
= 0.04) and more frequent vascular invasion (p = 0.10) and sum of nodule sizes (p = 0.06)
(Supplementary Table 2). There was no significant difference between LDLT and DDLT
groups regarding number of tumor nodules, histological grade or presence of bilobar
disease.
Post-LT HCC Recurrence and Survival
Tumor recurrence by stage and era is shown in Table 3. In the pre-MELD era, HCC
recurrence in DDLT recipients was limited to 1 patient who had T4b disease out of 21 (5%),
whereas 16 of 50 (32%) LDLT recipients had HCC recurrence, including 5 (10%) with less
advanced HCC (T0, 1 or 2). In comparison, all recurrences in both LDLT and DDLT
recipients in the MELD era occurred in those with advanced disease (>T2). HCC recurrence
was detected in 0 of 24 (0%) LDLT recipients with early HCC (≤T2), 11 of 25 (44%) LDLT
with advanced HCC (>T2), 0 of 42 (0%) DDLT recipients with early HCC, and 7 of 31
(23%) DDLT with advanced HCC.
There were more HCC recurrences in LDLT compared to DDLT recipients for the entire
cohort (28 LDLT, 8 DDLT recurrences, Figure 2a) as well as among the subset of MELD
era patients (Figure 2b). After a median post-transplant follow-up of 4.3 years in DDLT and
5.9 years in LDLT recipients, the 5-year unadjusted probability of HCC recurrence was 38%
in LDLT recipients and 11% in DDLT recipients (p = 0.0004). After adjusting for explant
tumor size, number of tumor nodules and presence of vascular invasion, HCC recurrence
rates remained higher in LDLT recipients (HR = 2.35, 95% CI 1.04–5.35; p = 0.04) (Figure
2c, Table 4a).However, in the MELD era, the association of LDLT with HCC recurrence
was present but not statistically significant in a similar model adjusted for tumor
characteristics (HR = 1.36, 95% CI 0.47–3.93; p = 0.57)(Table 4b).
The difference in HCC recurrence rates between LDLT and DDLT recipients in the entire
cohort was most striking during the first year post transplant (15% vs. 0%; p < 0.0001).
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Conditional on being recurrence-free at 1 year, and after adjusting for explant tumor size,
number of tumor nodules and presence of vascular invasion, the subsequent recurrence risks
for LDLT and DDLT were almost identical (HR = 1.20, 95% CI 0.48–2.98; p = 0.69).
LDLT recipients with early HCC recurrence were significantly more likely to have a larger
tumor diameter (p = 0.0008), a higher AFP level at the time of transplant (p = 0.0002), and
presence of grade 3 HCC on explant liver (p = 0.0004) (Supplementary Figure 1).
Survival was similar between LDLT and DDLT recipients for the entire cohort as well as the
MELD era patients (Figure 3a and 3b). The 5-year unadjusted survival probability was 59%
in LDLT recipients and 66% in DDLT recipients (HR=1.32; p = 0.27). The type of
transplant did not predict post-LT mortality in multivariable Cox models for the entire
cohort (HR = 1.25, 95% CI 0.69 – 2.26; p = 0.46) or in the subset of patients in the MELD
era (HR = 0.85, 95% CI 0.33 – 2.19; p = 0.74). Similarly, there was no difference in
recurrence-free survival between LDLT and DDLT recipients for the entire cohort (HR =
1.51, 95% CI 0.88 – 2.59; p = 0.13) or for those in the MELD era (HR = 1.23, 95% CI 0.55
– 2.74; p = 0.61) (Figures 4a and 4b).
A total of 39 LDLT and 27 DDLT patients died by the end of the study. HCC recurrence
was the cause of death in 24 patients (18 LDLT, 6 DDLT). Unadjusted survival from the
time of HCC recurrence to death was not statistically significantly different in the LDLT and
DDLT patients (median time to death 23 months LDLT, 36 months DDLT; p = 0.14). The
causes of death in the remaining patients included: cardiac arrest (2 LDLT, 3 DDLT),
recurrent hepatitis (2 LDLT, 2 DDLT), infection (4 LDLT, 2 DDLT), lymphoma and other
malignancies (0 LDLT, 3 DDLT), respiratory failure (3 LDLT, 1 DDLT), other (5 LDLT, 3
DDLT) and unknown (5 LDLT, 7 DDLT).
Survival from Time of Potential Living Donor Evaluation
To assess whether receiving an LDLT was associated with a survival benefit over waiting
for a DDLT, analysis from the time donor evaluation was performed. For this analysis, 219
patients with HCC known at the time of donor evaluation were included and 10 patients with
HCC diagnosed after donor evaluation were excluded. The adjusted risk of death from the
time of donor evaluation was similar for patients who received LDLT versus non-LDLT
(patients who received DDLT and those who continued to wait for but did not receive any
LT) for the entire cohort (HR = 0.73, 95% CI 0.36–1.45; p = 0.36) and in the MELD era
(HR = 0.90, 95% CI 0.35–2.33; p = 0.83) (Figures 5a and 5b).
Factors associated with HCC Recurrence, Survival, and Recurrence Free Survival Post
Transplant
In addition to transplant type, independent predictors of HCC recurrence for the entire
cohort included size of largest tumor nodule and number of tumor nodules on explant liver
(Table 4a). These tumor characteristics as well as the presence of vascular invasion
predicted HCC recurrence in the MELD era (Table 4b).
Post-LT mortality for the entire cohort was predicted only by AFP level at transplant (HR =
1.35, 95% CI 1.07–1.71; p = 0.01) (Table 4a) and for the MELD era by the diameter of the
largest nodule on explant and vascular invasion (Table 4b).
Similarly, AFP at transplant, greater size of the largest tumor nodule and number of tumor
nodules on explant predicted recurrence free survival for the entire cohort, while greater size
of the largest tumor nodule and presence of vascular invasion were predictors of recurrence
free survival for the MELD era patients (Tables 4a and 4b).
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Analysis of the early A2ALL experience which accrued prior to implementation of MELD
found a significantly higher rate of HCC recurrence among LDLT recipients compared to
DDLT recipients. Implementation of MELD had a major impact on prioritization for
patients with HCC within Milan criteria, resulting in a higher percentage of patients
undergoing DDLT and a lower percentage undergoing LDLT compared to the pre-MELD
era (Figure 1). The current analysis included a substantially larger sample size with 64%
enrolled in the MELD era. The unadjusted excess risk of HCC recurrence after LDLT
compared to DDLT was attenuated, but remained significant in the MELD era. Independent
predictors of HCC recurrence for the entire cohort included type of transplant, number of
tumor nodules and diameter of the largest nodule on explant liver.
In the A2ALL retrospective study, LDLT was associated with increased HCC recurrence
after stratifying by stage at explant; a multivariable analysis to determine factors associated
with HCC recurrence in this cohort was not feasible due to no recurrence in the DDLT
group. The lack of HCC recurrence among DDLT recipients and higher than expected
recurrence rate among LLDT recipients with early HCC (6/23) led to the proposal of “fast-
tracking” as an explanation for these findings (10). Fast-tracking a patient to LDLT could
theoretically negatively impact outcomes by inclusion of patients with inherently more
aggressive tumor biology. In the current study, the failure to demonstrate a significant
difference in HCC recurrence between LDLT and DDLT in the MELD era, after controlling
for tumor characteristics, may be a reflection of extreme MELD era prioritization for DDLT
mimicking the effect of LDLT “fast-tracking” and producing more similar recurrence rates.
In our current cohort, LDLT was significantly associated with HCC recurrence even after
adjusting for tumor characteristics for the entire cohort. The role of tumor biology on HCC
recurrence was most pronounced among LDLT recipients with recurrence within 1 year post
transplant. Fourteen (15%) LDLT, but none of the DDLT recipients, had HCC recurrence
within the first year post transplant. Tumor characteristics consistent with an aggressive
phenotype were noted in the patients with early recurrence; larger tumors, higher AFP, and
grade 3 HCC. It has been postulated that the rapidity of liver regeneration can have a
stimulatory effect on residual tumor cells, leading to higher HCC recurrence associated with
partial transplants. A recent animal model supports this hypothesis (11).
An extensive experience of LDLT has been reported from Asia where live donors are the
predominant source of grafts for transplant. Several authors have demonstrated tumor size
>5 cm in LDLT to be an independent predictor for HCC recurrence (12–18). This is in line
with our experience that demonstrates tumor size to be an independent predictor of HCC
recurrence. The significantly higher 5-year HCC recurrence rate in LDLT compared to
DDLT recipients is related to greater tumor burden in LDLT recipients (p = 0.03).
Recently, Bhangui et al. reported no difference in recurrence rates in LDLT versus DDLT
recipients, but did note a trend for poorer outcomes in LDLT recipients whose tumors
exceeded the Milan criteria (19). A major difference in their cohort compared to ours was
that the tumor characteristics and pre-transplant treatments were not significantly different
between DDLT and LDLT groups. This is likely related to DDLT not being limited to
patients within the Milan criteria in this European cohort. In contrast, DDLT prioritization in
the US is limited to those fulfilling Milan criteria.
Despite having more advanced tumors, the LDLT recipients were less likely to receive pre-
transplant LRT and had fewer treatment sessions when rendered. A lack of response to LRT
has been shown to be a predictor of HCC recurrence in DDLT (19–21). LRT followed by a
time period to assess tumor response (“ablate and wait” approach) may allow the tumor an
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opportunity to declare a potentially aggressive behavior prior to LT (22, 23). However, a
standardized approach of LRT has not been widely adopted among transplant centers.
Receipt of LRT did not emerge as a predictor of outcome in our cohort, possibly due to
heterogeneity in use of LRT among centers and the fact that we controlled for the effect of
LRT by analyzing explant tumor burden. LDLT recipients in our study also had significantly
higher AFP levels at donor evaluation and at transplant compared to the DDLT group.
Decline in AFP levels in response to LRT has been shown to predict improved overall and
post-LT survival rates (10, 24–27). Merani et al. reported that an AFP ≤400 ng/ml closest to
LT predicted better survival including patients who had an initial AFP >1000 ng/ml and a
decline to ≤400 ng/ml with LRT (28). Differences in HCC recurrence based on changes in
AFP levels could not be analyzed in our study because serial AFP levels were not collected.
The only independent predictor of survival was AFP at the time of transplant in the entire
cohort and tumor size and vascular invasion in the MELD era. Importantly, post-transplant
survival was comparable between DDLT and LDLT recipients even though LDLT recipients
in the entire cohort had a significantly higher rate of HCC recurrence after adjusting for
tumor characteristics. Our data suggest that LDLT may confer a survival advantage that is
unrelated to HCC recurrence.
Vakili et al. reported a significantly improved 5-year survival in LDLT compared to DDLT
recipients (81% vs. 58%; p = 0.023) despite a significantly higher HCC recurrence rate
among the LDLT group (29% vs. 12%; p < 0.05) (3). Improved survival in the LDLT group
may be related to the benefits of a superior quality of the graft due to potentially younger
donors and less cold ischemia time. In contrast to the A2ALL cohort, tumor characteristics
including AFP levels were not significantly different between the two groups. The only
significant predictor of survival in their study was the presence of poorly differentiated HCC
leading to death from HCC recurrence within 2.8 years of LDLT. To this end, some centers
have adopted tumor grade as a selection criterion for transplant regardless of tumor size and
number (29–31). Tumor grade was not used as a selection criterion for transplant in our
cohort and was not significantly different between LDLT and DDLT recipients, except
among the LDLT recipients with early HCC recurrence. Although tumor grade was missing
in 34% of patients, when tested in subset models in the entire cohort it was a significant
predictor of HCC recurrence (p=0.0003), and had a non-statistically significant trend for
survival (p = 0.08).
An important consideration in the decision of LDLT and DDLT is survival from the time of
donor evaluation, taking into account drop out and wait list mortality. In this study, there
was no difference in survival between patients who did or did not receive LDLT. However,
in another analysis of the A2ALL data, a survival benefit of LDLT was observed in patients
with HCC and a laboratory MELD exceeding 15 (32). It is plausible that higher MELD
scores prohibited LRT leading to an increased risk of drop out in those without a live donor.
Alternatively, patients with higher MELD may succumb to liver failure if timely transplant
is not feasible. Data from A2ALL suggest that HCC patients who are most likely to benefit
from LDLT are those with T3 or T4a tumors who are not eligible for MELD upgrade and
those with an unadjusted MELD > 15.
The strengths of this study include a large number of patients (N = 229), a long duration of
follow-up (median 4.95 years), and most importantly, LDLT and DDLT recipients were
comparable in that they all had a potential donor. The limitations include variability in
center practices regarding selection of candidates for LDLT based on tumor stage,
differences in use of LRT and inevitable differences in waiting time for DDLT in each
region.
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In conclusion, we believe that the higher HCC recurrence rate in LDLT recipients is due
primarily to more advanced HCC and less liver directed HCC therapy compared to DDLT,
as opposed to the type of transplant. Despite higher recurrence rates, overall survival was
not significantly different from DDLT. With the risk posed to the donor and the benefit of an
expedited transplant via LDLT being negated with the institution of HCC MELD upgrade
for patients with T2 tumors, it begs the question of the current role for LDLT in HCC. Our
data suggest that patients who are most likely to derive a benefit from LDLT are those with
tumors exceeding the Milan criteria. However, our findings also support the need for a
selection process in order to minimize HCC recurrence post-transplant. A mandated period
of observation after pre-transplant LRT to document response based on radiology and a
decline in AFP should be considered a prerequisite before proceeding with LDLT. Others, as
well as our data, support an elevated AFP level at the time of transplant predicting overall
survival (28,33). Changes in United Network for Organ Sharing prioritization for HCC, such
as a mandated waiting period before receiving a HCC MELD upgrade along with an
abolition of prioritization if AFP level exceeds 500 ng/ml in an attempt to eliminate
aggressive phenotypes, might motivate increased use of LDLT for HCC. Therefore, the
transplant community will need to even more so be judicious in the use of LDLT for HCC.
In the absence of a selection process for LDLT, both donors and recipients should be
informed of the increased risk of HCC recurrence post-transplant when this procedure is
performed in patients with tumors beyond the Milan criteria.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Cumulative probability over time of LDLT, DDLT, remaining alive on the waitlist, and
death without transplant, from the first living donor evaluation (based on the cumulative
incidence function) for (a) HCC patients in the Pre-MELD Era and (b) HCC patients in the
MELD era.
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Probability of freedom from HCC recurrence by time since LDLT or DDLT for (a) all HCC
patients (unadjusted), (b) HCC patients in the MELD era (unadjusted), and (c) all HCC
patients (adjusted based on a Cox regression model, with both LDLT and DDLT groups
presented for the overall average baseline characteristic values of two liver nodules, largest
nodule 3.5 cm, and without vascular invasion).
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Unadjusted probability of patient survival by time since LDLT or DDLT for (a) all HCC
patients and (b) HCC patients in the MELD era.
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Unadjusted probability of recurrence-free survival by time since LDLT or DDLT for (a) all
HCC patients and (b) HCC patients in the MELD era.
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Adjusted probability of patient mortality by time from first living donor evaluation, for (a)
all HCC patients and (b) HCC patients in the MELD era, both based on Cox regression
models with both LDLT and DDLT groups presented for the average baseline characteristic
values (55 years old, beyond Milan, AFP=10, lab MELD=12, and without ablation).
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Table 1
Characteristics of HCC patients at evaluation of first living donor
LDLT (n=100) DDLT (n=97) No Transplant (n=32)
Characteristics† Mean ± SD or % Mean ± SD or % p-value‡ Mean ± SD or %
Male Gender 75 76 0.8332 68.8
Age, years 55.2 ± 8.0 53.9 ± 8.5 0.3070 54.7 ± 10.5
Race
 White 80 82 0.8879 75
 African American 2 2 9.4
 Other 18 16 15.6
HCV etiology of cirrhosis 78 78 0.9981 71.9
AFP (ng/mL)
 <20 48 62 0.0038 43
 20–400 32 33 37
 >400 20 5 20
Log AFP 1.67 ± 1.04 1.18 ± 0.70 0.0002 1.81 ± 1.17
MELD 12.1 ± 4.5 12.7 ± 4.7 0.3754 12.1 ± 4.7
Tumor stage 0.0007
 T0* 3 4 4
 T1 7 15 7
 T2 31 51 56
 T3 44 15 26
 T4 15 14 7
Beyond Milan 59 30 <0.0001 33
Beyond UCSF 42 20 0.0015 16
Diameter of largest nodule, cm 4.3 ± 2.8 3.2 ± 1.7 0.0009 3.9 ± 2.9
HCC ablation before donor
 evaluation 45 65 0.0090 50
†
Numbers of missing values for [LDLT, DDLT, no transplant] were [0,0,0] for gender, age, and race, [24,12,2] for HCV etiology of cirrhosis, and
[2–16, 2–15, 1–7] for all other variables.
‡
p-values for comparison of LDLT and DDLT for age, log AFP, MELD, and diameter of largest nodule computed from t-test; and for all other
characteristics from chi-square test.
*
Five patients received HCC treatment prior to enrollment and had been down staged to T0 and the other 2 patients were diagnosed with HCC after
enrollment.
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Table 2
Characteristics of HCC patients at transplant
LDLT (n=100) DDLT (n=97)
Characteristics† Mean ± SD or % Mean ± SD or % p-value‡
At Transplant
 AFP (ng/mL) 0.0065
  <20 48 59
  20–400 31 36
  >400 21 5
 Log AFP 1.7 ± 1.1 1.2 ± 0.7 0.0003
 Donor Age (years) 35.0 ± 10.2 42.3 ± 17.7 0.0019
 Cold Ischemia Time (minutes) 65.6 ± 60.4 409 ± 195 <0.0001
 MELD 13.3 ± 4.6 13.8 ± 6.4 0.5067
 Beyond Milan 52 26 0.0003
 Beyond UCSF 35 14 0.0015
 HCC ablation from donor evaluation to LT 31 49 0.0102
 HCC ablation ever before LT 59 73 0.0355
 No. of ablations since diagnosis 1.2 ± 1.5 1.8 ± 1.7 0.0137
 Days from donor evaluation to
 LT 77.7 ± 106 180.5 ± 258 0.0004
Explant Pathology
 Tumor stage 0.2441
  T0 6 13
  T1 7 12
  T2 31 31
  T3 35 24
  T4 21 20
 Beyond Milan 56 44 0.0963
 Beyond UCSF 48 34 0.0573
 Bilobar HCC 42 33 0.2160
 Diameter of largest nodule (cm) 4.3 ± 2.5 3.5 ± 1.9 0.0140
 No. of tumor nodules 2.4 ± 1.8 2.1 ± 1.7 0.3189
 Vascular invasion 23 12 0.0658
 Total Length of Nodules (cm) 6.4± 4.0 5.4± 3.3 0.0906
 Tumor grade 0.9719
  G1 29 29
  G2 54 53
  G3 16 18
†
Number of missing values for [LDLT, DDLT] were [14,12] for AFP, [1,24] for donor age, [23,3] for cold ischemia time, [9,3] for Milan, [16,5]
for UCSF, and [0, 0–1] for other transplant variables, and [2–7,4–14] for explants variables except for tumor grade, [32,35].
‡
p-values for comparison of LDLT and DDLT. Two-sample t-tests and chi-square tests were used for continuous variables and proportions,
respectively.
HCC= Hepatocellular carcinoma, LDLT= Living donor liver transplant, DDLT= Deceased donor liver transplant, LT= Liver transplant
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